Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11389408 | 0.84 | ALDH1A1 (0.45) | POLBLMNAALDH1A1MEN1CYP3A4 | |
| SCHEMBL29868078 | 0.82 | MAPT (0.38) | KDM4EPOLBLMNAALDH1A1KMT2A | |
| SCHEMBL29868349 | 0.82 | ALDH1A1 (0.33) | KDM4EPOLBHTTALDH1A1GAA | |
| SCHEMBL25533294 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1MEN1CYP3A4HPGD | |
| SCHEMBL25529274 | 0.78 | TYR (0.37) | KDM4EPOLBHTTALDH1A1TSHR | |
| SCHEMBL20026452 | 0.72 | KDM4E (0.47) | KDM4EHTTALDH1A1HPGDGAA | |
| SCHEMBL16672604 | 0.72 | MAPT (0.38) | KDM4EPOLBLMNAALDH1A1MEN1 | |
| SCHEMBL2280549 | 0.71 | L3MBTL1 (0.54) | KDM4EPOLBHTTALDH1A1TSHR | |
| SCHEMBL2540404 | 0.68 | MAPT (0.38) | KDM4EPOLBALDH1A1MEN1CYP3A4 | |
| SCHEMBL29868351 | 0.68 | MAPT (0.36) | KDM4EPOLBLMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | KDM4E 3309/4885POLB 1012/4885HTT 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.